<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00556062</url>
  </required_header>
  <id_info>
    <org_study_id>PRO-INF-4005</org_study_id>
    <nct_id>NCT00556062</nct_id>
  </id_info>
  <brief_title>Phase IV Clinical Trial of an Influenza Split Vaccine Anflu</brief_title>
  <official_title>The Clinical Trial for Three Consecutive Lots of Influenza Split Vaccine Anflu by Randomized, Double-Blind and Controlled Design</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sinovac Biotech Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sinovac Biotech Co., Ltd</source>
  <brief_summary>
    <textblock>
      To evaluate the safety and immunogenicity of the three consecutive lots of an seasonal split
      influenza vaccine Anflu in adults, a randomized, double-blind and controlled clinical trial
      was conducted in 560 subjects in Tianjin City of China.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Haemagglutination-inhibition (HI) antibody titer of influenza A H1N1, influenza A H3N2 and influenza B</measure>
    <time_frame>0, 21 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>local and systematic adverse reactions after vaccination</measure>
    <time_frame>within 3 days after vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">566</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>1: Lot 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2: Lot 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3: Lot 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4: control vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>seasonal split influenza vaccine</intervention_name>
    <description>0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime</description>
    <arm_group_label>1: Lot 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>seasonal split influenza vaccine</intervention_name>
    <description>0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime</description>
    <arm_group_label>2: Lot 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>seasonal split influenza vaccine</intervention_name>
    <description>0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime</description>
    <arm_group_label>3: Lot 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>seasonal split influenza vaccine</intervention_name>
    <description>0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime</description>
    <arm_group_label>4: control vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adults aged 18-60 years old

          -  Be able to show legal identity card for the sake of recruitment Without vaccination
             history of seasonal split influenza vaccine in the recent 3 years

          -  Not participate in any other clinical trials during the study

          -  Not receive any immunosuppressive agents during and one month prior to the study

          -  Be able to understand and sign the informed consent.

        Exclusion Criteria:

          -  Woman： Who breast-feeding or planning to become pregnant during the study

          -  Any history of allergic reactions; was allergic to any component of the vaccine, such
             as eggs or ovalbumin

          -  Any history of severe adverse reactions to vaccines, such as anaphylaxis, hives,
             respiratory difficulty, angioedema, or abdominal pain

          -  Autoimmune disease or immunodeficiency

          -  Acute episode of chronic diseases or conditions, including chronic hepatitis,
             hypertension, diabetes mellitus and cardiovascular diseases

          -  Guillain-Barre Syndrome

          -  Women subjects with positive urinary pregnancy test

          -  Any history of immunosuppressive medications or cytotoxic medications or inhaled
             corticosteroids within the past six months (with the exception of corticosteroid nasal
             spray for allergic rhinitis or topical corticosteroids for an acute uncomplicated
             dermatitis)

          -  Axillary temperature &gt;37.0 centigrade at the time of dosing

          -  Psychiatric condition that precludes compliance with the protocol; past or present
             psychoses; past or present bipolar disorder requiring therapy that has not been well
             controlled on medication for the past two years; disorder requiring lithium; or
             suicidal ideation occurring within five years prior to enrollment

          -  Any medical, psychiatric, social condition, occupational reason or other
             responsibility that, in the judgment of the investigator, is a contraindication to
             protocol participation or impairs a volunteer's ability to give informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhilun Zhang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tianjin centers for Disease Control and Prevention</affiliation>
  </overall_official>
  <verification_date>November 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2007</study_first_submitted>
  <study_first_submitted_qc>November 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2007</study_first_posted>
  <last_update_submitted>November 8, 2007</last_update_submitted>
  <last_update_submitted_qc>November 8, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 9, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

